AVBP
ArriVent BioPharma, Inc. Common Stock
NASDAQ: AVBP · HEALTHCARE · BIOTECHNOLOGY
$31.09
+3.46% today
Updated 2026-04-30
Market cap
$1.34B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.32
Dividend yield
—
52W range
$16 – $32
Volume
0.5M
ArriVent BioPharma, Inc. Common Stock (AVBP) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
-44.7%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
-30.0%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
+0.8%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+7.4%
2025-11-10
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-26 | $-0.78 | +4.9% | $22.75 | $21.43 | -5.8% |
| 2025-11-10 | $-0.83 | -5.1% | $18.05 | $19.38 | +7.4% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.82 | $-0.78 | +4.9% | — | — |
| 2025-09-30 | $-0.79 | $-0.83 | -5.1% | — | — |
| 2025-06-30 | $-0.76 | $-0.90 | -18.4% | — | — |
| 2025-03-31 | $-0.73 | $-1.90 | -160.3% | — | — |
| 2024-12-31 | $-0.46 | $-0.60 | -30.4% | — | — |
| 2024-09-30 | $-0.54 | $-0.61 | -13.0% | — | — |
| 2024-06-30 | $-0.51 | $-0.65 | -27.5% | — | — |
| 2024-03-31 | $-1.30 | $-0.70 | +46.0% | — | — |
| 2023-12-31 | $-1.10 | $-0.70 | +36.4% | — | — |
Frequently asked questions
Has ArriVent BioPharma, Inc. Common Stock beaten earnings estimates?
ArriVent BioPharma, Inc. Common Stock has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of -44.7% over the last 4 quarters.
How does AVBP stock react to earnings?
AVBP stock has moved an average of +0.8% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.